Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There was no association between use of ferric carboxymaltose, iron sucrose, baseline PTH, vitamin D levels, ferritin, hemoglobin, or receipt of more than 2 iron infusions and hypophosphatemia (Table S3).
Source: Risk factors for hypophosphatemia following iron infusion. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
To determine the risk factors for developing hypophosphatemia post iron infusion, patients were initially categorized into those who developed hypophosphatemia at any time in the 3 mo following their initial iron infusion and those who did not.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Prevalence, predictors, and natural history of hypophosphatemia following iron infusion
Study design awaiting verification · JBMR Plus · 2025
Original publication title
Prevalence, predictors, and natural history of hypophosphatemia following iron infusion
© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Iron deficiency is the leading cause of anemia, which affects 1 quarter of the adult population globally. Intravenous iron is a well-established treatment option and is generally well tolerated. However, there is increasing recognition that it can cause hypophosphatemia, which can result in fatigue, nausea, myalgia, weakness, and osteomalacia. We sought to determine the prevalence, natural history, and predictors of hypophosphatemia following iron infusion in a tertiary hospital. All adult patients who received 1 or more iron infusions between January 1, 2019 and December 31, 2021 were included in this retrospective study.
A total of 2367 subjects were identified, receiving a total of 7063 infusions over the study period. Hypophosphatemia was defined as a serum phosphate level of <0.75 mmol/L (<2.32 mg/dL), with severity classified as mild 0.65-0.75 mmol/L (2.01-2.31 mg/dL), moderate 0.32-0.64 mmol/L (0.99-1.98 mg/dL), or severe <0.32 mmol/L (<0.99 mg/dL). Prevalence of hypophosphatemia was 48.9%, with the highest prevalence from day 4 to 20 post-iron infusion (39.3%-44.1%). Risk factors were receipt of iron polymaltose (odds ratio [OR] 2.33, CI 1.71-3.19, p < .0001), receipt of ferric carboxymaltose (OR 1.79, CI 1.29-2.48, p = .001), male gender (OR 1.35, CI 1.09-1.66, p = .006), and multiple iron infusions (OR 1.56, CI 1.20-2.03, p = .001).
Risk was reduced in recipients with higher baseline phosphate (OR 0.18, CI 0.11-0.28, p < .0001), higher baseline creatinine (OR 0.83, CI 0.74-0.92, p = .001), and increased weight (OR 0.99, CI 0.99-1.00, p = .016). Risk factors for moderate to severe hypophosphatemia were the same, except that gender became nonsignificant, while increasing age (OR 0.99, CI 0.99-1.00, p = .002) was also associated with reduced risk. These findings may aid clinicians in identifying those at greatest risk of developing significant hypophosphatemia, thereby preventing adverse outcomes.
Authors’ abstract
Abstract
Iron deficiency is the leading cause of anemia, which affects 1 quarter of the adult population globally. Intravenous iron is a well-established treatment option and is generally well tolerated. However, there is increasing recognition that it can cause hypophosphatemia, which can result in fatigue, nausea, myalgia, weakness, and osteomalacia. We sought to determine the prevalence, natural history, and predictors of hypophosphatemia following iron infusion in a tertiary hospital. All adult patients who received 1 or more iron infusions between January 1, 2019 and December 31, 2021 were included in this retrospective study.
A total of 2367 subjects were identified, receiving a total of 7063 infusions over the study period. Hypophosphatemia was defined as a serum phosphate level of <0.75 mmol/L (<2.32 mg/dL), with severity classified as mild 0.65-0.75 mmol/L (2.01-2.31 mg/dL), moderate 0.32-0.64 mmol/L (0.99-1.98 mg/dL), or severe <0.32 mmol/L (<0.99 mg/dL). Prevalence of hypophosphatemia was 48.9%, with the highest prevalence from day 4 to 20 post-iron infusion (39.3%-44.1%). Risk factors were receipt of iron polymaltose (odds ratio [OR] 2.33, CI 1.71-3.19, p < .0001), receipt of ferric carboxymaltose (OR 1.79, CI 1.29-2.48, p = .001), male gender (OR 1.35, CI 1.09-1.66, p = .006), and multiple iron infusions (OR 1.56, CI 1.20-2.03, p = .001).
Risk was reduced in recipients with higher baseline phosphate (OR 0.18, CI 0.11-0.28, p < .0001), higher baseline creatinine (OR 0.83, CI 0.74-0.92, p = .001), and increased weight (OR 0.99, CI 0.99-1.00, p = .016). Risk factors for moderate to severe hypophosphatemia were the same, except that gender became nonsignificant, while increasing age (OR 0.99, CI 0.99-1.00, p = .002) was also associated with reduced risk. These findings may aid clinicians in identifying those at greatest risk of developing significant hypophosphatemia, thereby preventing adverse outcomes.
Publication and source details
Original title: Prevalence, predictors, and natural history of hypophosphatemia following iron infusion
Chloe Dawson; Lai-Ming Kathleen Pak; Eldho Paul; Naomi Szwarcbard; Kathryn Hackman
JBMR Plus · 2025
Corresponding author: Chloe Dawson, Department of Endocrinology and Diabetes, Alfred Health, 55 Commercial Rd, Melbourne, VIC 3004, Australia (cgdaws92@gmail.com)© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:18:12.991071+00:00
DOI: 10.1093/jbmrpl/ziaf014 · PMC12723802